HUT67164A - Contrast agents for ultrasound imaging and process for production of them - Google Patents
Contrast agents for ultrasound imaging and process for production of them Download PDFInfo
- Publication number
- HUT67164A HUT67164A HU9203845A HU9203845A HUT67164A HU T67164 A HUT67164 A HU T67164A HU 9203845 A HU9203845 A HU 9203845A HU 9203845 A HU9203845 A HU 9203845A HU T67164 A HUT67164 A HU T67164A
- Authority
- HU
- Hungary
- Prior art keywords
- fatty acid
- imaging agent
- human serum
- serum albumin
- dispersion
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 41
- 239000002872 contrast media Substances 0.000 title description 12
- 238000012285 ultrasound imaging Methods 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 61
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 59
- 229930195729 fatty acid Natural products 0.000 claims description 59
- 239000000194 fatty acid Substances 0.000 claims description 59
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 54
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 54
- 239000006185 dispersion Substances 0.000 claims description 38
- 239000012216 imaging agent Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 31
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000007789 gas Substances 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 238000002059 diagnostic imaging Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000001112 coagulating effect Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 9
- 235000021360 Myristic acid Nutrition 0.000 description 9
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 229910001882 dioxygen Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002961 echo contrast media Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011265 2D-echocardiography Methods 0.000 description 1
- 108010056388 Albunex Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/803,293 US5196183A (en) | 1991-12-04 | 1991-12-04 | Contrast agents for ultrasound imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUT67164A true HUT67164A (en) | 1995-02-28 |
Family
ID=25186146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9203845A HU9203845D0 (en) | 1991-12-04 | 1992-12-04 | Contrast materials for making ultrasonic pictures and method for producing them |
| HU9203845A HUT67164A (en) | 1991-12-04 | 1992-12-04 | Contrast agents for ultrasound imaging and process for production of them |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9203845A HU9203845D0 (en) | 1991-12-04 | 1992-12-04 | Contrast materials for making ultrasonic pictures and method for producing them |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5196183A (xx) |
| EP (1) | EP0547654A1 (xx) |
| JP (1) | JP2769077B2 (xx) |
| KR (1) | KR930012039A (xx) |
| CN (1) | CN1073880A (xx) |
| AU (1) | AU2857292A (xx) |
| BR (1) | BR9204841A (xx) |
| CA (1) | CA2084432A1 (xx) |
| CZ (1) | CZ352992A3 (xx) |
| FI (1) | FI925526A (xx) |
| HU (2) | HU9203845D0 (xx) |
| IL (1) | IL103951A0 (xx) |
| IS (1) | IS3955A (xx) |
| MX (1) | MX9206980A (xx) |
| MY (1) | MY134715A (xx) |
| NO (1) | NO924679L (xx) |
| PL (1) | PL296827A1 (xx) |
| SK (1) | SK352992A3 (xx) |
| TN (1) | TNSN92111A1 (xx) |
| TW (1) | TW221791B (xx) |
| UY (1) | UY23515A1 (xx) |
| YU (1) | YU103792A (xx) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
| US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
| US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
| US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
| US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
| US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
| US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| WO1994007417A1 (en) * | 1992-10-06 | 1994-04-14 | Molecular Biosystems, Inc. | Method of ultrasonic imaging of body cavities |
| GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
| US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
| CA2164813C (en) | 1993-07-30 | 2009-11-24 | Ernest G. Schutt | Stabilized microbubble compositions for ultrasound |
| US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
| US5509896A (en) * | 1994-09-09 | 1996-04-23 | Coraje, Inc. | Enhancement of thrombolysis with external ultrasound |
| US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
| GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
| US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
| US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| CA2252617A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
| DK0977597T3 (da) | 1996-09-11 | 2003-05-05 | Imarx Pharmaceutical Corp | Forbedrede fremgangsmåder til diagnostisk billeddannelse ved hjælp af et kontrastmiddel og en vasodilatator. |
| US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US6638230B2 (en) * | 2001-07-31 | 2003-10-28 | Koninklijke Philips Electronics N.V. | Apparatus and method of frequency compounding to perform contrast imaging |
| US7737097B2 (en) * | 2003-06-27 | 2010-06-15 | Lam Research Corporation | Method for removing contamination from a substrate and for making a cleaning solution |
| US8364256B2 (en) * | 2004-11-15 | 2013-01-29 | Coraje, Inc. | Method and apparatus of removal of intravascular blockages |
| CN100574811C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用微粒类助剂及其应用 |
| CN100574809C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用氟碳乳剂类助剂及其应用 |
| EP1901310B1 (en) * | 2006-09-13 | 2013-02-27 | Holtec International, Inc. | Fuel storage rack and method for storing fuel assemblies in an underwater environment having lateral access loading |
| EP2668961A4 (en) | 2010-11-19 | 2016-07-06 | Univ Sapporo Medical | PHARMACEUTICAL COMBINATION PREPARATION |
| EP3127915B1 (en) | 2014-04-02 | 2020-08-26 | Nitto Denko Corporation | Rbp-derived targeting molecule and utilization thereof |
| GB201415681D0 (en) * | 2014-09-04 | 2014-10-22 | Cambridge Entpr Ltd And President And Fellows Of Harvard College | Protien Capsules |
| WO2022014762A1 (ko) * | 2020-07-16 | 2022-01-20 | ㈜에어레인 | 연소배가스의 이산화탄소 포집 및 질소 농축을 동시에 수행하는 다단 막분리공정 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
| US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
| DE3834705A1 (de) * | 1988-10-07 | 1990-04-12 | Schering Ag | Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln |
| PT81498B (pt) * | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
| DE3529195A1 (de) * | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung |
| US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
| US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
-
1991
- 1991-12-04 US US07/803,293 patent/US5196183A/en not_active Expired - Fee Related
-
1992
- 1992-11-24 AU AU28572/92A patent/AU2857292A/en not_active Abandoned
- 1992-11-28 EP EP92203684A patent/EP0547654A1/en not_active Withdrawn
- 1992-12-01 CZ CS923529A patent/CZ352992A3/cs unknown
- 1992-12-01 SK SK3529-92A patent/SK352992A3/sk unknown
- 1992-12-02 JP JP4323081A patent/JP2769077B2/ja not_active Expired - Lifetime
- 1992-12-02 TW TW081109668A patent/TW221791B/zh active
- 1992-12-03 MY MYPI92002220A patent/MY134715A/en unknown
- 1992-12-03 IS IS3955A patent/IS3955A/is unknown
- 1992-12-03 IL IL103951A patent/IL103951A0/xx unknown
- 1992-12-03 MX MX9206980A patent/MX9206980A/es unknown
- 1992-12-03 YU YU103792A patent/YU103792A/sh unknown
- 1992-12-03 PL PL29682792A patent/PL296827A1/xx unknown
- 1992-12-03 CA CA002084432A patent/CA2084432A1/en not_active Abandoned
- 1992-12-03 TN TNTNSN92111A patent/TNSN92111A1/fr unknown
- 1992-12-04 HU HU9203845A patent/HU9203845D0/hu unknown
- 1992-12-04 FI FI925526A patent/FI925526A/fi not_active Application Discontinuation
- 1992-12-04 KR KR1019920023284A patent/KR930012039A/ko not_active Application Discontinuation
- 1992-12-04 NO NO92924679A patent/NO924679L/no unknown
- 1992-12-04 BR BR9204841A patent/BR9204841A/pt not_active Application Discontinuation
- 1992-12-04 HU HU9203845A patent/HUT67164A/hu unknown
- 1992-12-04 UY UY23515A patent/UY23515A1/es unknown
- 1992-12-04 CN CN92115180A patent/CN1073880A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX9206980A (es) | 1993-06-01 |
| CZ352992A3 (en) | 1993-09-15 |
| MY134715A (en) | 2007-12-31 |
| CA2084432A1 (en) | 1993-06-05 |
| NO924679D0 (no) | 1992-12-04 |
| NO924679L (no) | 1993-06-07 |
| PL296827A1 (en) | 1993-12-27 |
| IL103951A0 (en) | 1993-05-13 |
| AU2857292A (en) | 1993-06-17 |
| IS3955A (is) | 1993-06-05 |
| FI925526A (fi) | 1993-06-05 |
| JP2769077B2 (ja) | 1998-06-25 |
| HU9203845D0 (en) | 1993-03-29 |
| TW221791B (xx) | 1994-03-21 |
| YU103792A (sh) | 1995-12-04 |
| US5196183A (en) | 1993-03-23 |
| EP0547654A1 (en) | 1993-06-23 |
| SK352992A3 (en) | 1994-12-07 |
| CN1073880A (zh) | 1993-07-07 |
| BR9204841A (pt) | 1993-06-08 |
| TNSN92111A1 (fr) | 1993-06-08 |
| UY23515A1 (es) | 1993-05-21 |
| KR930012039A (ko) | 1993-07-20 |
| JPH05194278A (ja) | 1993-08-03 |
| FI925526A0 (fi) | 1992-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT67164A (en) | Contrast agents for ultrasound imaging and process for production of them | |
| DE69732568T2 (de) | Druckbeständige protein-mikrosphäre als ultraschallkontrastmittel | |
| JP3247374B2 (ja) | 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法 | |
| AU676148B2 (en) | Improvements in contrast agents, consisting of galactose particles | |
| US5141738A (en) | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof | |
| DE69636486T2 (de) | Gasemulsionen, die durch fluorierte Ether mit niedrigen Ostwaldkoeffizienten stabilisiert sind | |
| US5637289A (en) | Contrast agents, consisting of galactose particles | |
| EP0077752B1 (de) | Flüssige Mischung zur Aufnahme und Stabilisierung von Gasbläschen zur Verwendung als Kontrastmittel für die Ultraschalldiagnostik und deren Herstellung | |
| US5695740A (en) | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide | |
| US5718884A (en) | Microbubble-based contrast agents with crosslinked and reduced proteinaceous shells | |
| JP2842453B2 (ja) | 生体内に注入可能な安定な微小泡懸濁液 | |
| DE69432370T2 (de) | Proteinverkapselte, unlösliche, gasenthaltende Mikrokügelchen, deren Herstellung und Anwendung als bildgebende Mittel für Ultraschall | |
| DE69738406T2 (de) | Verbesserungen in oder an Kontrastmitteln | |
| US6106807A (en) | Use of methylenemalondiester derivatives for the production of gas-containing microparticles for ultrasound diagnosis, as well as media that contain said particles | |
| JPH11509522A (ja) | 中断された超音波により誘導される微小気泡キャビテーション画像形成 | |
| NZ207853A (en) | Ultrasound contrast agent containing microparticles and gas micro-bubbles | |
| JPH06510758A (ja) | 造影剤におけるまたは造影剤に関する改良 | |
| HUT67156A (en) | Encapsulated particles useful as contrast agent in ultrasound and x-ray imagong and process for production of them | |
| US5648062A (en) | Contrast agents consisting of galactose particles | |
| DE60006683T2 (de) | Methode um ein gasenthaltendes konstrastmittel mit einer spülflüssigkeit zu mischen vor der verabrechnung in einer kontinuierlichen infustion | |
| JPH08310971A (ja) | 超音波診断用造影剤 | |
| DE69921317T2 (de) | Gas und destabilisierungsmittel enthaltende ultraschallkontrastmitteldispersionen | |
| JPH09502173A (ja) | 超音波造影剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFC4 | Cancellation of temporary protection due to refusal |